Achieve Life Sciences (ACHV) vs ArriVent BioPharma (AVBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed ArriVent BioPharma (AVBP) over the past year, gaining 51.9% versus a loss of 14.6%. ArriVent BioPharma is the larger company by market cap ($821.5 million vs $657.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | AVBP |
|---|---|---|
| Share price | $6.38 | $16.66 |
| Market cap | $657.79M | $821.47M |
| 1-day change | -8.46% | -0.77% |
| YTD return | +28.37% | -17.20% |
| 1-year return | +51.90% | -14.61% |
| 5-year return | -20.45% | — |
| EPS (TTM) | $-1.69 | $-3.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-54.65M | $-166.31M |
| 52-week high | $8.64 | $35.83 |
| 52-week low | $2.62 | $11.36 |
| Distance from 52-week high | -26.16% | -53.50% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +121.79% | +29.41% |
| Average volume | 1.41M | 1.00M |
| Shares outstanding | 103.10M | 49.31M |
| Employees | 28 | 77 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACHV has outperformed AVBP by 66.5 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Healthcare · Biotechnology · 28 employees
About ArriVent BioPharma
AVBP stock →ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
Healthcare · Biotechnology · 77 employees
ACHV vs AVBP FAQ
Which is bigger, Achieve Life Sciences or ArriVent BioPharma?
ArriVent BioPharma (AVBP) is larger, with a market capitalization of $821.47M compared with $657.79M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or AVBP?
ACHV returned +51.90% over the past 12 months, compared with -14.61% for AVBP (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and ArriVent BioPharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.